Inhibition of hepatic glycogen phosphorylase is a promising treatment strategy for attenuating hyperglycemia in type 2 diabetes. Crystallographic studies indicate, however, that selectivity between glycogen phosphorylase in skeletal muscle and liver is unlikely to be achieved. Furthermore, glycogen phosphorylase activity is critical for normal skeletal muscle function, and thus fatigue may represent a major development hurdle for this therapeutic strategy. We have carried out the first systematic evaluation of this important issue. The rat gastrocnemius-plantaris-soleus (GPS) muscle was isolated and perfused with a red cell suspension, containing 3 mol/l glycogen phosphorylase inhibitor (GPi) or vehicle (control). After 60 min, the GPS muscle was snap-frozen (rest, n ؍ 11 per group) or underwent 20 s of maximal contraction (n ؍ 8, control; n ؍ 9, GPi) or 10 min of submaximal contraction (n ؍ 10 per group). GPi pretreatment reduced the activation of the glycogen phosphorylase a form by 16% at rest, 25% after 20 s, and 44% after 10 min of contraction compared with the corresponding control. AMP-mediated glycogen phosphorylase activation was impaired only at 10 min (by 21%). GPi transiently reduced muscle lactate production during contraction, but other than this, muscle energy metabolism and function remained unaffected at both contraction intensities. These data indicate that glycogen phosphorylase inhibition aimed at attenuating hyperglycaemia is unlikely to negatively impact muscle metabolic and functional capacity. Diabetes 54: 2453-2459, 2005 G lycogen phosphorylase catalyzes the breakdown of glycogen to glucose-1-phosphate in liver and tissues with high and fluctuating energy demands. Glycogen phosphorylase exists in two interconvertible forms (a and b); the proportion that exists in each form is regulated by phosphorylation. The less active b form is transformed by phosphorylation to the more active a form. In skeletal muscle, the transformation from b to a is regulated by changes in intracellular concentrations of AMP, inosine monophosphate (IMP), and inorganic phosphate and by glycogen phosphorylase kinase activation, all of which increase during contraction. Glycogen phosphorylase kinase also exists in two forms, glycogen phosphorylase kinase a and glycogen phosphorylase kinase b. Glycogen phosphorylase kinase b activity is increased in the presence of elevated intracellular calcium (Ca ϩ2 ) and cAMP, mediated by contraction (1-4) and adrenaline (5-7), respectively, which then phosphorylates and activates glycogen phosphorylase kinase a. Phosphorylated glycogen phosphorylase kinase a then phosphorylates and transforms glycogen phosphorylase b to its more active a form. On cessation of contraction, calcium is sequestered back into the sarcoplasmic reticulum, and the elevated concentrations of ADP, AMP, and inorganic phosphate are used to regenerate muscle ATP and phosphocreatine (PCr) stores. Glycogen phosphorylase a form is subsequently dephosphorylated by the action of protein phosphatases, wher...